Latest & greatest articles for tuberculosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on tuberculosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on tuberculosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for tuberculosis

21. Risk of tuberculosis in patients with immune-mediated diseases on biological therapies: a population-based study in a tuberculosis endemic region

Risk of tuberculosis in patients with immune-mediated diseases on biological therapies: a population-based study in a tuberculosis endemic region Real-world epidemiological data on the risk of tuberculosis (TB) in patients with immune-mediated diseases treated with biologics are scarce in TB endemic areas. We investigated the incidence of TB in a population-based setting and stratified the risk of TB among different biological therapies.We collected medical data from a territory-wide

2019 EvidenceUpdates

22. Six versus 12 Months of Anti Tubercular Therapy in Patients With Biopsy Proven Spinal Tuberculosis: A Single Center, Open Labeled, Prospective Randomized Clinical Trial-A Pilot study

Six versus 12 Months of Anti Tubercular Therapy in Patients With Biopsy Proven Spinal Tuberculosis: A Single Center, Open Labeled, Prospective Randomized Clinical Trial-A Pilot study A single center pilot study, open labeled, prospective randomized clinical trial.To compare six versus 12 months of anti TB therapy in patients with biopsy proven spinal TB.There is no clear consensus or evidence based guidelines for the duration of treatment of spinal tuberculosis. We studied if 6 and 12 months (...) of anti tubercular therapy (ATT) had equivalent outcomes at 24 months from completion of therapy.A prospective randomized open labeled clinical trial of 6 versus 12 months ATT in patients with biopsy proven spinal-vertebral tuberculosis. The primary end point was absence of recurrence 24 months after completing therapy. Secondary end points were clinical cure at the end of therapy, significant adverse effect of ATT, need for delayed surgery, and residual neurological dysfunction.Hundred patients

2019 EvidenceUpdates

23. Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study

Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study Latent tuberculosis infection (LTBI) management is now a critical component of the World Health Organization's End TB Strategy.In this randomised controlled trial (Chinese Clinical Trial Registry identifier ChiCTR-IOR-15007202), two short-course regimens with rifapentine plus isoniazid (a 3-month once-weekly regimen and a 2-month twice-weekly

2019 EvidenceUpdates

24. Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: a systematic review

Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: a systematic review The global loss to follow-up (LTFU) rate among drug-resistant tuberculosis (DR-TB) patients remains high at 15%. We conducted a systematic review to explore interventions to reduce LTFU during DR-TB treatment.We searched for studies published between January 2000 and December 2017 that provided any form of psychosocial or material support for patients with DR

2019 EvidenceUpdates

25. Programmatic management of latent tuberculosis infection in the European Union

Programmatic management of latent tuberculosis infection in the European Union SCIENTIFIC ADVICE Programmatic management of latent tuberculosis infection in the European Union www.ecdc.europa.euECDC SCIENTIFIC ADVICE Programmatic management of latent tuberculosis infection in the European Union ii This guidance was commissioned by ECDC and coordinated by Senia Rosales Klintz, Netta Beer and Marieke J. van der Werf with the support of Helena de Carvalho Gomes (ECDC). The inventory of expert (...) Kingdom), and its members: Judith Bruchfeld (Sweden); Josie Garrett (United Kingdom); Walter Haas (Germany); Einar Heldal (Norway); Rein Houben (United Kingdom); Philip LoBue (USA); Mike Mandelbaum (United Kingdom); Alberto Matteelli (Italy); Giovanni Battista Migliori (Italy); Ivan Solovic (Slovakia); and Martina Vašáková (Czech Republic). Suggested citation: European Centre for Disease Prevention and Control. Programmatic management of latent tuberculosis infection in the European Union. Stockholm

2019 European Centre for Disease Prevention and Control - Public Health Guidance

26. Approaches to detecting tuberculosis in children and youth

Approaches to detecting tuberculosis in children and youth This practice point provides a framework for initiating investigation in children suspected of having infection with  Mycobacterium tuberculosis  (Mtb). Some areas in Canada have a high burden of tubercular disease, with Indigenous populations being most at risk. Tuberculosis (TB) can present either as an acute or subacute illness and both primary or reactivation infection can cause pulmonary or multisystem disease (...) . Tuberculin skin tests and interferon-γ release assays can be used to support a suspected diagnosis. TB elimination in Canada is possible but requires improving social determinants of health, one of the major factors contributing to the spread of TB in populations at risk. Keywords: Bacille-Calmette-Guérin; Break of contact; Latent tuberculosis infection; Mycobacterium tuberculosis; Tuberculosis  

2019 Canadian Paediatric Society

27. A systematic review and meta-analysis of the effect of HIV status on the incidence of tuberculosis disease among individuals with latent Mycobacterium tuberculosis infection

A systematic review and meta-analysis of the effect of HIV status on the incidence of tuberculosis disease among individuals with latent Mycobacterium tuberculosis infection Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

28. The global prevalence of latent tuberculosis: a systematic review and meta-analysis

The global prevalence of latent tuberculosis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

29. The role of IP-10 in tuberculosis treatment monitoring: a systematic review

The role of IP-10 in tuberculosis treatment monitoring: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

30. Risk of depression in pulmonary tuberculosis

Risk of depression in pulmonary tuberculosis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2019 PROSPERO

31. Association between HIV infection and multidrug-resistant tuberculosis in Africa and Asia :a systematic review and meta-analysis

Association between HIV infection and multidrug-resistant tuberculosis in Africa and Asia :a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

32. The diagnostic test accuracy of breath test by electronic nose or other devices versus other tests for tuberculosis (TB) in patients with TB or suspected with TB: a systematic review and meta-analysis

The diagnostic test accuracy of breath test by electronic nose or other devices versus other tests for tuberculosis (TB) in patients with TB or suspected with TB: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

33. Efficacy, safety, and completion of rifampicin/rifapentine containing regimens for treatment of latent tuberculosis: an individual patient data meta-analysis

Efficacy, safety, and completion of rifampicin/rifapentine containing regimens for treatment of latent tuberculosis: an individual patient data meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

34. Dzherelo (Immunoxel) as adjunctive treatment in patients with pulmonary tuberculosis: a systematic review and meta-analysis of clinical trials

Dzherelo (Immunoxel) as adjunctive treatment in patients with pulmonary tuberculosis: a systematic review and meta-analysis of clinical trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

35. Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and individual patient data meta-analysis

Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and individual patient data meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

36. Barriers to and enablers of uptake of and adherence to antiretroviral therapy (ART) in the context of integrated HIV and tuberculosis (TB) treatment among adults in sub-Saharan Africa: a protocol for a systematic review

Barriers to and enablers of uptake of and adherence to antiretroviral therapy (ART) in the context of integrated HIV and tuberculosis (TB) treatment among adults in sub-Saharan Africa: a protocol for a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete

2019 PROSPERO

37. Impact of metformin on the risk and treatment of tuberculosis: A systematic review and meta-analysis

Impact of metformin on the risk and treatment of tuberculosis: A systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

38. Impact of inclusion, dose and duration of pyrazinamide on efficacy and safety outcomes in tuberculosis: systematic review and meta-analysis

Impact of inclusion, dose and duration of pyrazinamide on efficacy and safety outcomes in tuberculosis: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

39. Systematic review of association between silica/silicosis and tuberculosis

Systematic review of association between silica/silicosis and tuberculosis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

40. Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay: a systematic review and meta-analysis

Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO